Intrinsic Value of S&P & Nasdaq Contact Us

Tiziana Life Sciences Ltd TLSA NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • GB • USD

SharesGrow Score
43/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Tiziana Life Sciences Ltd (TLSA) — Analyst outlook / Analyst consensus target is. Based on 3 analyst ratings, the consensus is bullish — 2 Buy, 1 Hold.

Analysts estimate Earnings Per Share (EPS) of $-0.13 and revenue of $0.00B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $-0.22 vs est $-0.13 (missed -70.1%). Analyst accuracy: 59%.

TLSA Analyst Ratings

Buy
3
Ratings
2 Buy
1 Hold
Based on 3 analysts giving stock ratings to Tiziana Life Sciences Ltd in the past 3 months
Rating breakdown
Buy
2 67%
Hold
1 33%
67%
Buy
2 analysts
33%
Hold
1 analysts
0%
Sell
0 analysts

EPS Estimates — TLSA

59%
Analyst Accuracy
Inaccurate
1 year compared
Actual vs Estimate
2024 Actual –$0.22 vs Est –$0.13 ▼ 41.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.

Revenue Estimates — TLSA

Revenue Trend
Analysts expect stable revenue going forward.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message